Sandoz and Pear Therapeutics announce launch of reSET for treatment of patients with Substance Use Disorder
- reSET is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD)
- Adding reSET to outpatient therapy significantly improved abstinence in substances of abuse and treatment retention compared to standard of care alone
- Sandoz and Novartis continue to embrace digital technologies to enhance R&D and deliver better outcomes for patients
###
For further information, contact:Novartis Media Relations Central media line: +41 61 324 2200 media.relations@novartis.com | Novartis Global Media Relations Eric Althoff +41 61 324 7999 eric.althoff@novartis.com |
Sandoz US Communications Leslie Pott +1 609 627 5287 leslie.pott@sandoz.com | Sandoz Global Communications Chris Lewis +49 8024 476 1906 chris.lewis@sandoz.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Richard Pulik | +1 212 830 2448 |
Pierre-Michel Bringer | +41 61 324 1065 | Cory Twining | +1 212 830 2407 |
Thomas Hungerbuehler | +41 61 324 8425 | ||
Isabella Zinck | +41 61 324 7188 |